SPRY4-IT1 Research Articles

Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.

Breast cancer is the most frequent malignancy and the leading cause of cancer death among females. Long noncoding RNAs (lncRNAs) are under investigation as novel prognostic biomarkers in cancer. The aim of the study was to investigate the expression, clinical implications and prognostic significance of lncRNA SPRY4-IT1, and to identify the predictive value of SPRY4-IT1 on the outcome of chemotherapy in breast cancer patients undergoing neoadjuvant chemotherapy (NACT). Bioinformatics indicated SPRY4-IT1 was related to chemo-resistance in breast cancer. SPRY4-IT1 expression was assessed by qRT-PCR in breast cancer tissues and matched normal breast tissues (n=26 pairs). SPRY4-IT1 expression was also detected by In situ hybridization (ISH) in 60 paraffin slices with complete clinical datum. In this study, SPRY4-IT1 was significantly more expressed in cancer tissues than in normal tissues (P<0.05). Increased SPRY4-IT1 expression was significantly corre¬lated with increased rates of lymph node metastasis (P=0.002) and recurrence (P=0.017). Both were independent factors of SPRY4-IT1 expression (P<0.05). High-SPRY4-IT1 patients had significantly lower overall survival and disease-free survival. High SPRY4-IT1 expression indicated poor clinical response in the whole group, luminal A subgroup and luminal B subgroup (P<0.05) and pathological complete response in the whole group. Overexpression of SPRY4-IT1 promoted chemo-resistance of MCF-7 and MDA-MB-231 cells to epirubicin. SPRY4-IT1 has the potential to be a biomarker to predict NACT efficacy and prognosis in breast cancer patients.

SPRY4-IT1 contributes to increased cell proliferation by activating zinc finger protein 703 expression in non-small cell lung cancer

Objective To observe the long non-coding RNA SPRY4-IT1 expression level in non-small cell lung cancer and its biological funciton in aspects of cell proliferation. Methods Real-time quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) was used to measure the expression of SPRY4-IT1 in 32 non-small cell lung cancer (NSCLC) patients. Loss of function approach was then applied to confirm the biological function, especially cell prolifieration in cultured human lung cancer cells A5549, by cell counting kit-8 (CCK-8) and clonogenic assay. We further used western blot to reveal the activation of zinc finger protein 703 (ZNF703) by SPRY4-IT1. Results The SPRY4-IT1 relative expression level were 1.12±0.78 and 3.24±2.01 respectively for tumor tissue and norma tissue of NSCLC patients with statistical difference (t=5.56, P=0.001); SPRY4-IT1 expression level were significant decreased by transinfection of si-SPRY4-IT1 in A549 cells. A549 cell clone formation ability was significantly reduced by traninfection of si-SPRY4-IT1. The mRNA expression of ZNF703 were 0.61±0.07 and 0.96±0.08 for si-SPRY4-IT1 and si-nc A549 cells with statistical difference (P=0.001); The protein expression of ZNF703 were 0.08±0.02 and 0.12±0.03 for si-SPRY4-IT1 and si-nc A549 cells with statistical difference (P=0.001). Conclusion SPRY4-IT1 expression is up-regulated in tumor tissue of non-small cell lung cancer patients and the SPRY4-IT1/ZNF703 axis might contribute to increased proliferation ability of lung cancer cells. Key words: SPRY4-IT1; Non-small cell lung cancer; Long chain of non encoding RNA; Proliferation ability